KLRG1 and systemic lupus erythematosus: In conclusion, these studies suggest that KLRG1 is mostly positively correlated with disease severity in autoimmune diseases [18, 81], can serve as a marker of disease progression in patients with IBM [27, 85] and SLE [80], and has potential as a therapeutic target in patients with IBM [79].